0
Editorials |

Steroids for Acute Exacerbations of COPD : How Long Is Enough?

Matthew B. Stanbrook, MD; Roger S. Goldstein, MB, ChB, FCCP
Author and Funding Information

Affiliations: Toronto, Canada 
 ,  Drs. Stanbrook and Goldstein are from the Division of Respiratory Medicine, University of Toronto, Toronto, Ontario, Canada.

Correspondence to: Roger S. Goldstein, MB, ChB, FCCP, Division of Respiratory Medicine, West Park Hospital, 82 Buttonwood Ave, Toronto, Ontario M6M 2J5, Canada; e-mail: roger.goldstein@utoronto.ca



Chest. 2001;119(3):675-676. doi:10.1378/chest.119.3.675
Text Size: A A A
Published online

Extract

It is now 20 years since Richard Albert and colleagues1 published the first randomized, double-blind, placebo-controlled trial of systemic glucocorticoids in the treatment of acute exacerbations of COPD. In this landmark study, a regimen of IV methylprednisolone four times daily for 3 days was found to produce an early increase in FEV1 relative to placebo treatment. Continued improvement was observed up to 72 h with ongoing treatment.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543